|
US2016040136A1
|
|
Novel prrs virus inducing type i interferon in susceptible cells
|
|
US2016030349A1
|
|
Nanoparticles, methods of preparation, and uses thereof
|
|
CN106456741A
|
|
Recombinant classical swine fever virus (csfv) comprising substitution in the tav epitope of the e2 protein
|
|
WO2015149921A1
|
|
Inhaler
|
|
KR20160096196A
|
|
Treatment of metabolic disorders in feline animals
|
|
WO2015091322A1
|
|
Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals
|
|
KR20160089525A
|
|
Improved pharmaceutical compositions of pimobendan
|
|
WO2015075003A1
|
|
Reducing pain in male animals during castration
|
|
WO2015026912A1
|
|
Porcine circovirus type 2 (pcv2) subunit vaccine
|
|
WO2015024653A1
|
|
Inhaler
|
|
WO2015024650A1
|
|
Inhaler
|
|
KR20160045687A
|
|
Inhaler
|
|
WO2015007759A1
|
|
Etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
|
|
WO2014197445A2
|
|
Protocol management system and methods for livestock operations
|
|
CN105246505A
|
|
ORF2 protein of PCV2 subtype a (PCV2a) for use in cross-protection
|
|
EP2981269A1
|
|
Treatment of metabolic disorders in equine animals
|
|
WO2014150822A2
|
|
Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
|
|
CN105026419A
|
|
Quantification of vaccine compositions
|
|
SG11201505930TA
|
|
Porcine parvovirus 5b, methods of use and vaccine
|
|
WO2014122248A1
|
|
Kit-of-parts
|
